Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 175
Filter
1.
Rev Mal Respir ; 41(5): 331-342, 2024 May.
Article in French | MEDLINE | ID: mdl-38609767

ABSTRACT

INTRODUCTION: The second COPD Biennial organized by the COPD working group of the French Society of Respiratory Diseases took place in Paris (Cochin) on 13th December 2023. STATE OF THE ART: Major trends in 2023 were discussed; they encompassed concepts, definitions, biologics, care pathways, pulmonary rehabilitation and complex situations entailed by respiratory infections, cardiovascular comorbidities and pulmonary hypertension, and modalities of oxygen therapy and ventilation. PERSPECTIVES: The different talks underlined major changes in COPD including the concepts of pre-COPD, etiotypes, health trajectories and new definitions of exacerbation. Recent results in biologics for COPD open the door to new pharmacological options. Assessment of current care pathways in France highlighted some causes for concern. For example, pulmonary rehabilitation is a key but insufficiently practiced element. Respiratory infections require careful assessment and treatments. Diagnosis and treatment of cardiovascular comorbidities and pulmonary hypertension are of paramount importance. As of late, oxygen therapy and ventilation modalities have evolved, and are beginning to afford more personalized options. CONCLUSIONS: As regards COPD, a personalized approach is crucial, placing the patient at the center of the care pathway and facilitating coordination between healthcare providers.


Subject(s)
Critical Pathways , Pulmonary Disease, Chronic Obstructive , Societies, Medical , Humans , Pulmonary Disease, Chronic Obstructive/therapy , Pulmonary Disease, Chronic Obstructive/epidemiology , Pulmonary Disease, Chronic Obstructive/rehabilitation , France/epidemiology , Critical Pathways/organization & administration , Critical Pathways/standards , Critical Pathways/trends , Societies, Medical/organization & administration , Societies, Medical/standards , Patient-Centered Care/organization & administration , Patient-Centered Care/trends , Patient-Centered Care/standards , Pulmonary Medicine/organization & administration , Pulmonary Medicine/trends , Pulmonary Medicine/methods , Pulmonary Medicine/standards , Congresses as Topic
3.
Mayo Clin Proc ; 96(5): 1250-1261, 2021 05.
Article in English | MEDLINE | ID: mdl-33958056

ABSTRACT

The administration of spike monoclonal antibody treatment to patients with mild to moderate COVID-19 is very challenging. This article summarizes essential components and processes in establishing an effective spike monoclonal antibody infusion program. Rapid identification of a dedicated physical infrastructure was essential to circumvent the logistical challenges of caring for infectious patients while maintaining compliance with regulations and ensuring the safety of our personnel and other patients. Our partnerships and collaborations among multiple different specialties and disciplines enabled contributions from personnel with specific expertise in medicine, nursing, pharmacy, infection prevention and control, electronic health record (EHR) informatics, compliance, legal, medical ethics, engineering, administration, and other critical areas. Clear communication and a culture in which all roles are welcomed at the planning and operational tables are critical to the rapid development and refinement needed to adapt and thrive in providing this time-sensitive beneficial therapy. Our partnerships with leaders and providers outside our institutions, including those who care for underserved populations, have promoted equity in the access of monoclonal antibodies in our regions. Strong support from institutional leadership facilitated expedited action when needed, from a physical, personnel, and system infrastructure standpoint. Our ongoing real-time assessment and monitoring of our clinical program allowed us to improve and optimize our processes to ensure that the needs of our patients with COVID-19 in the outpatient setting are met.


Subject(s)
Antiviral Agents/administration & dosage , COVID-19 , Critical Pathways , Home Infusion Therapy , SARS-CoV-2 , Spike Glycoprotein, Coronavirus , Antibodies, Monoclonal/administration & dosage , COVID-19/epidemiology , COVID-19/therapy , Clinical Protocols , Critical Pathways/organization & administration , Critical Pathways/trends , Efficiency, Organizational , Home Infusion Therapy/methods , Home Infusion Therapy/standards , Humans , Intersectoral Collaboration , Organizational Culture , Program Development/methods , SARS-CoV-2/immunology , SARS-CoV-2/isolation & purification , Severity of Illness Index , Spike Glycoprotein, Coronavirus/antagonists & inhibitors , Spike Glycoprotein, Coronavirus/immunology , United States/epidemiology
4.
Indian Pediatr ; 58(4): 383-390, 2021 Apr 15.
Article in English | MEDLINE | ID: mdl-33883314

ABSTRACT

JUSTIFICATION: The unprecedented COVID-19 pandemic has had a formidable impact on Indian health care. With no sight of its end as yet, various establishments including the smaller clinics and nursing homes are restarting full operations. Hence, there is the need for recommendations to allow safe practice ensuring the safety of both the heath care worker (HCW) and patients. PROCESS: Indian Academy of Pediatrics organized an online meeting of subject experts on 27 July, 2020. A committee was formed comprising of pediatricians, pediatric and neonatal intensivists, and hospital administrators. The committee held deliberations (online and via emails) and a final consensus was reached by November, 2020. OBJECTIVES: To develop recommendations to provide a safe and practical healthcare facility at clinics and small establishments during COVID times. RECOMMENDATIONS: The key recommendation to practise safely in this setting are enumerated. Firstly, organizing the out-patient department (OPD). Secondly, appropriate personal protective equipment (PPE) to provide protection to the individual. Thirdly, decontamination/disinfection of various common surfaces and equipment to prevent transmission of infection from fomites. Next, maintaining the heating ventilation and air conditioning (HVAC) to provide a stress-free, comfortable, and safe environment for patients and HCWs. Finally, steps to effectively manage COVID-19 exposures in a non-COVID-19 facility. All these measures will ensure safe practice during these unprecedent times in clinics and smaller establishments.


Subject(s)
COVID-19 , Critical Pathways , Infection Control , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Neonatology , Pediatrics , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19/therapy , COVID-19/transmission , Critical Pathways/organization & administration , Critical Pathways/standards , Critical Pathways/trends , Humans , India/epidemiology , Infection Control/instrumentation , Infection Control/methods , Infection Control/organization & administration , Intersectoral Collaboration , Neonatology/organization & administration , Neonatology/standards , Organizational Innovation , Pediatrics/organization & administration , Pediatrics/standards , SARS-CoV-2 , Societies, Medical
5.
BMC Pregnancy Childbirth ; 21(1): 310, 2021 Apr 19.
Article in English | MEDLINE | ID: mdl-33874913

ABSTRACT

BACKGROUND: Induction of labour (IOL) is one of the most commonly performed interventions in maternity care, with outpatient cervical ripening increasingly offered as an option for women undergoing IOL. The COVID-19 pandemic has changed the context of practice and the option of returning home for cervical ripening may now assume greater significance. This work aimed to examine whether and how the COVID-19 pandemic has changed practice around IOL in the UK. METHOD: We used an online questionnaire to survey senior obstetricians and midwives at all 156 UK NHS Trusts and Boards that currently offer maternity services. Responses were analysed to produce descriptive statistics, with free text responses analysed using a conventional content analysis approach. FINDINGS: Responses were received from 92 of 156 UK Trusts and Boards, a 59% response rate. Many Trusts and Boards reported no change to their IOL practice, however 23% reported change in methods used for cervical ripening; 28% a change in criteria for home cervical ripening; 28% stated that more women were returning home during cervical ripening; and 24% noted changes to women's response to recommendations for IOL. Much of the change was reported as happening in response to attempts to minimise hospital attendance and restrictions on birth partners accompanying women. CONCLUSIONS: The pandemic has changed practice around induction of labour, although this varied significantly between NHS Trusts and Boards. There is a lack of formal evidence to support decision-making around outpatient cervical ripening: the basis on which changes were implemented and what evidence was used to inform decisions is not clear.


Subject(s)
Attitude of Health Personnel , COVID-19 , Cervical Ripening , Critical Pathways , Labor, Induced , Adult , Ambulatory Care/methods , COVID-19/epidemiology , COVID-19/prevention & control , Clinical Decision-Making , Critical Pathways/organization & administration , Critical Pathways/trends , Female , Humans , Infection Control/methods , Labor, Induced/methods , Labor, Induced/trends , Maternal Health Services/trends , Organizational Innovation , Policy Making , Pregnancy , Surveys and Questionnaires , United Kingdom
6.
Medicine (Baltimore) ; 100(15): e25495, 2021 Apr 16.
Article in English | MEDLINE | ID: mdl-33847662

ABSTRACT

ABSTRACT: While the new Coronavirus Disease 2019 (COVID-19) pandemic rapidly spread across the world, South America was reached later in relation to Asia, Europe and the United States of America (USA). Brazil concentrates now the largest number of cases in the continent and, as the disease speedily progressed throughout the country, prompt and challenging operational strategies had to be taken by institutions caring for COVID-19 and non-COVID-19 patients in order to assure optimal workflows, triage, and management. Although hospitals in the USA, Europe and Asia have shared their experience on this subject, little has been discussed about such strategies in South America or by the perspective of outpatient centers, which are paramount in the radiology field. This article shares the guidelines adopted early in the pandemic by a nationwide outpatient healthcare center composed by a network of more than 200 patient service centers and nearly 2,000 radiologists in Brazil, discussing operational and patient management strategies, staff protection, changes adopted in the fellowship program, and the effectiveness of such measures.


Subject(s)
Ambulatory Care , COVID-19 , Change Management , Civil Defense , Critical Pathways , Strategic Planning , Technology, Radiologic , Ambulatory Care/methods , Ambulatory Care/organization & administration , Ambulatory Care/statistics & numerical data , Brazil/epidemiology , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19/prevention & control , Civil Defense/organization & administration , Civil Defense/statistics & numerical data , Critical Pathways/organization & administration , Critical Pathways/trends , Humans , Organizational Innovation , Practice Guidelines as Topic , SARS-CoV-2 , Strategic Planning/standards , Strategic Planning/statistics & numerical data , Technology, Radiologic/methods , Technology, Radiologic/organization & administration , Technology, Radiologic/statistics & numerical data
9.
Chest ; 160(1): 175-186, 2021 07.
Article in English | MEDLINE | ID: mdl-33667491

ABSTRACT

BACKGROUND: SARS-CoV-2 aerosolization during noninvasive positive-pressure ventilation may endanger health care professionals. Various circuit setups have been described to reduce virus aerosolization. However, these setups may alter ventilator performance. RESEARCH QUESTION: What are the consequences of the various suggested circuit setups on ventilator efficacy during CPAP and noninvasive ventilation (NIV)? STUDY DESIGN AND METHODS: Eight circuit setups were evaluated on a bench test model that consisted of a three-dimensional printed head and an artificial lung. Setups included a dual-limb circuit with an oronasal mask, a dual-limb circuit with a helmet interface, a single-limb circuit with a passive exhalation valve, three single-limb circuits with custom-made additional leaks, and two single-limb circuits with active exhalation valves. All setups were evaluated during NIV and CPAP. The following variables were recorded: the inspiratory flow preceding triggering of the ventilator, the inspiratory effort required to trigger the ventilator, the triggering delay, the maximal inspiratory pressure delivered by the ventilator, the tidal volume generated to the artificial lung, the total work of breathing, and the pressure-time product needed to trigger the ventilator. RESULTS: With NIV, the type of circuit setup had a significant impact on inspiratory flow preceding triggering of the ventilator (P < .0001), the inspiratory effort required to trigger the ventilator (P < .0001), the triggering delay (P < .0001), the maximal inspiratory pressure (P < .0001), the tidal volume (P = .0008), the work of breathing (P < .0001), and the pressure-time product needed to trigger the ventilator (P < .0001). Similar differences and consequences were seen with CPAP as well as with the addition of bacterial filters. Best performance was achieved with a dual-limb circuit with an oronasal mask. Worst performance was achieved with a dual-limb circuit with a helmet interface. INTERPRETATION: Ventilator performance is significantly impacted by the circuit setup. A dual-limb circuit with oronasal mask should be used preferentially.


Subject(s)
COVID-19 , Continuous Positive Airway Pressure , Disease Transmission, Infectious/prevention & control , Noninvasive Ventilation , Air Filters , Benchmarking/methods , COVID-19/therapy , COVID-19/transmission , Continuous Positive Airway Pressure/adverse effects , Continuous Positive Airway Pressure/instrumentation , Continuous Positive Airway Pressure/methods , Critical Pathways/standards , Critical Pathways/trends , Humans , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Noninvasive Ventilation/adverse effects , Noninvasive Ventilation/instrumentation , Noninvasive Ventilation/methods , Research Design , Respiratory Function Tests/methods , SARS-CoV-2 , Treatment Outcome , Ventilators, Mechanical
10.
Adv Ther ; 38(3): 1397-1403, 2021 03.
Article in English | MEDLINE | ID: mdl-33590446

ABSTRACT

The availability of pangenotypic direct-acting antivirals for treatment of hepatitis C (HCV) has provided an opportunity to simplify patient pathways. Recent clinical practice guidelines have recognised the need for simplification to ensure that elimination of HCV as a public health concern remains a priority. Despite the move towards simplified treatment algorithms, there remains some complexity in the recommendations for the management of genotype 3 patients with compensated cirrhosis. In an era where additional clinical trial data are not anticipated, clinical guidance should consider experience gained in real-world settings. Although more experience is required for some pangenotypic therapeutic options, on the basis of published real-world data, there is already sufficient evidence to consider a simplified approach for genotype 3 patients with compensated cirrhosis. The coronavirus disease 2019 (COVID-19) pandemic has highlighted the need to minimise the need for complex patient pathways and clinical practice guidelines need to continue to evolve in order to ensure that patient outcomes remain optimised.


Subject(s)
COVID-19 , Communicable Disease Control , Critical Pathways , Disease Eradication , Hepatitis C , Antiviral Agents/pharmacology , COVID-19/epidemiology , COVID-19/prevention & control , Communicable Disease Control/methods , Communicable Disease Control/organization & administration , Critical Pathways/standards , Critical Pathways/trends , Disease Eradication/methods , Disease Eradication/organization & administration , Global Health/trends , Hepatitis C/epidemiology , Hepatitis C/therapy , Humans , Practice Guidelines as Topic , SARS-CoV-2
11.
Med Sci (Paris) ; 37(2): 159-166, 2021 Feb.
Article in French | MEDLINE | ID: mdl-33591259

ABSTRACT

Pediatric brain cancers represent the most frequent solid tumors and the leading cause of cancer-driven mortality in children. Pediatric High Grade Gliomas display a very poor prognosis. Among these, DIPG (Diffuse Intrinsic Pontine Gliomas), localized to the brain stem, cannot benefit from a total exeresis due to this critical location and to their highly infiltrating nature. Radiotherapy remains the standard treatment against these tumors for almost five decades, and attempts to improve the prognosis of patients with chemotherapy or targeted therapies have failed. Thanks to the rise of high throughput sequencing, the knowledge of molecular alterations in pediatric gliomas strongly progressed and allowed to highlight distinct biomolecular entities and to establish more accurate diagnoses. In this review, we summarize this new information and the perspectives that it brings for clinical strategies.


TITLE: L'art de la guerre appliqué aux DIPG - Connais ton ennemi. ABSTRACT: Les tumeurs cérébrales pédiatriques représentent la principale cause de mortalité par cancer chez l'enfant. Alors que l'exérèse complète a une valeur pronostique dans certains gliomes de haut grade, les DIPG (diffuse intrinsic pontine gliomas) ne peuvent en bénéficier du fait d'une localisation critique au niveau du tronc cérébral et de leur caractère infiltrant. La radiothérapie demeure le traitement de référence contre ces tumeurs depuis bientôt cinquante ans, et les tentatives pour améliorer le pronostic vital des patients à l'aide de chimiothérapies ou de thérapies ciblées se sont révélées infructueuses. La connaissance des altérations moléculaires dans ces gliomes a fortement progressé cette dernière décennie, grâce aux progrès du séquençage à haut débit. Cela a permis de révéler des entités distinctes au niveau moléculaire et de préciser des diagnostics discriminants. Dans cette revue, nous faisons le point sur ces nouvelles connaissances et les perspectives qu'elles apportent en termes de stratégies cliniques.


Subject(s)
Brain Neoplasms/therapy , Glioma/therapy , Medical Oncology/trends , Age of Onset , Brain Neoplasms/epidemiology , Brain Neoplasms/pathology , Child , Critical Pathways/trends , Glioma/epidemiology , Glioma/pathology , Humans , Medical Oncology/methods , Prognosis
12.
Elife ; 102021 02 16.
Article in English | MEDLINE | ID: mdl-33588991

ABSTRACT

Before the coronavirus 2019 (COVID-19) pandemic began, antimicrobial resistance (AMR) was among the top priorities for global public health. Already a complex challenge, AMR now needs to be addressed in a changing healthcare landscape. Here, we analyse how changes due to COVID-19 in terms of antimicrobial usage, infection prevention, and health systems affect the emergence, transmission, and burden of AMR. Increased hand hygiene, decreased international travel, and decreased elective hospital procedures may reduce AMR pathogen selection and spread in the short term. However, the opposite effects may be seen if antibiotics are more widely used as standard healthcare pathways break down. Over 6 months into the COVID-19 pandemic, the dynamics of AMR remain uncertain. We call for the AMR community to keep a global perspective while designing finely tuned surveillance and research to continue to improve our preparedness and response to these intersecting public health challenges.


Subject(s)
Anti-Bacterial Agents , COVID-19 Drug Treatment , COVID-19 , Critical Pathways , Drug Resistance, Bacterial/physiology , Global Health/trends , Anti-Bacterial Agents/supply & distribution , Anti-Bacterial Agents/therapeutic use , COVID-19/epidemiology , COVID-19/prevention & control , Communicable Disease Control/methods , Communicable Disease Control/organization & administration , Critical Pathways/organization & administration , Critical Pathways/trends , Humans , SARS-CoV-2
13.
Am J Kidney Dis ; 77(5): 777-785, 2021 05.
Article in English | MEDLINE | ID: mdl-33388404

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic required transplant nephrologists, surgeons, and care teams to make decisions about the full spectrum of transplant program operations and clinical practices in the absence of experience or data. Initially, across the country, there was a reduction in kidney transplant procedures and a striking pause in the conduct of living donation and living-donor transplant surgeries. Aspects of candidate evaluation and follow-up rapidly converted to telehealth. Months into the pandemic, much has been learned from experiences worldwide, yet many questions remain. In this Perspective, we reflect on some of the practice decisions made by the transplant community in the initial response to the pandemic and consider lessons learned, including those related to the risks, benefits, and logistical considerations of proceeding with versus delaying deceased-donor transplantation, living donation, and living-donor transplantation during the pandemic. We review the evolution of therapeutic strategies for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and their use in transplant recipients, current consensus related to immunosuppression management in infected transplant recipients, and emerging information on vaccination against SARS-CoV-2. We share our thoughts on research priorities, discuss the areas in which we are still practicing with uncertainty, and look ahead to the next phase of the pandemic response.


Subject(s)
COVID-19 , Critical Pathways , Immunosuppression Therapy/methods , Kidney Failure, Chronic , Kidney Transplantation/methods , COVID-19/epidemiology , COVID-19/prevention & control , Clinical Decision-Making , Critical Pathways/organization & administration , Critical Pathways/trends , Humans , Infection Control/methods , Kidney Failure, Chronic/epidemiology , Kidney Failure, Chronic/surgery , SARS-CoV-2 , Telemedicine/methods , Time-to-Treatment , Tissue Donors/statistics & numerical data , Transplant Recipients
17.
Oncologist ; 26(2): e338-e341, 2021 02.
Article in English | MEDLINE | ID: mdl-33111460

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic may have affected cancer management. We aimed to evaluate changes in every oncology care pathway essential step, from screening to treatment, during the pandemic. Monthly oncological activity differences between 2019 and 2020 (screening tests, histopathological analyzes, multidisciplinary tumor board meetings (MTBMs), diagnostic announcement procedures (DAPs), and treatments were calculated in two French areas experiencing different pandemic intensity (Reims and Colmar). COVID-19 has had a dramatic impact in terms of screening (-86% to -100%), diagnosis (-39%), and surgical treatment (-30%). This global decrease in all essential oncology care pathway steps contrasted with the relative stability of chemotherapy (-9%) and radiotherapy use (-16%). Outbreak occurred earlier and with more intensity in Colmar but had a comparable impact in both areas regarding MTMBs and DAPs. The current ONCOCARE-COV study is still in progress and with a longer follow-up to analyze postlockdown situation.


Subject(s)
COVID-19/prevention & control , Infection Control/standards , Medical Oncology/trends , Neoplasms/therapy , Pandemics/prevention & control , COVID-19/epidemiology , COVID-19/immunology , COVID-19/virology , COVID-19 Testing/standards , Critical Pathways/standards , Critical Pathways/statistics & numerical data , Critical Pathways/trends , France/epidemiology , Humans , Mass Screening/standards , Mass Screening/statistics & numerical data , Mass Screening/trends , Medical Oncology/organization & administration , Medical Oncology/standards , Medical Oncology/statistics & numerical data , Neoplasms/diagnosis , Neoplasms/immunology , Patient Care Team/organization & administration , Patient Care Team/standards , Patient Care Team/statistics & numerical data , SARS-CoV-2/isolation & purification , SARS-CoV-2/pathogenicity , Telemedicine/standards
18.
Postgrad Med J ; 97(1147): 280-285, 2021 May.
Article in English | MEDLINE | ID: mdl-32371406

ABSTRACT

STUDY PURPOSE: Out-of-hospital cardiac arrests (OHCA) in the young population have only been examined in a limited number of regional studies. Hence, we sought to describe OHCA characteristics and predictors of survival to hospital discharge for the young Irish population. STUDY DESIGN: An observational analysis of the national Irish OHCA register for all OHCAs aged ≤35 years between January 2012 and December 2017 was performed. The young population was categorised into three age groups: ≤1 year, 1-15 years and 16-35 years. Multivariable logistic regression was used to determine the independent predictors of survival to hospital discharge. RESULTS: A total of 1295 OHCAs aged ≤35 years (26.9% female, median age 25 (IQR 17-31)) had resuscitation attempted. OHCAs in those aged ≥16 years (n=1005) were more likely to happen outside the home (38.5% vs 22.8%, p<0.001) and be of non-medical aetiology (59% vs 27.6%, p<0.001) compared with those aged <16 years (n=290). Asphyxiation, trauma and drug overdoses accounted for over 90% of the non-medical OHCAs for those 16-35 years. Overall survival to hospital discharge for the cohort was 5.1%; survival was non-significantly higher for those aged 16-35 years compared with those aged 1-15 years (6.0%, vs 2.8% p=0.93). Independent predictors of survival to hospital discharge included bystander witnessed OHCA, a shockable initial rhythm and a bystander defibrillation attempt. CONCLUSIONS: The high prevalence of non-medical OHCAs and the OHCA location need to be considered when developing OHCA care pathways and preventative strategies to reduce the burden of OHCAs in the young population.


Subject(s)
Asphyxia/complications , Critical Pathways/trends , Drug Overdose/complications , Emergency Medical Services , Out-of-Hospital Cardiac Arrest , Wounds and Injuries/complications , Adolescent , Adult , Asphyxia/epidemiology , Asphyxia/prevention & control , Cardiopulmonary Resuscitation/methods , Drug Overdose/epidemiology , Drug Overdose/prevention & control , Emergency Medical Services/methods , Emergency Medical Services/organization & administration , Emergency Medical Services/standards , Female , Humans , Infant , Ireland/epidemiology , Male , Out-of-Hospital Cardiac Arrest/etiology , Out-of-Hospital Cardiac Arrest/mortality , Out-of-Hospital Cardiac Arrest/therapy , Patient Discharge/statistics & numerical data , Preventive Health Services , Quality Improvement , Registries/statistics & numerical data , Survival Analysis , Wounds and Injuries/epidemiology , Wounds and Injuries/prevention & control
19.
J Intensive Care Med ; 36(5): 612-616, 2021 May.
Article in English | MEDLINE | ID: mdl-33323033

ABSTRACT

BACKGROUND: Covid-19 pandemic has resulted in the development of severe and persistent respiratory failure requiring long term ventilatory support. This necessitates the need for a reliable and easy to implement tracheostomy protocol given the concern for viral transmission risk to the involved healthcare personnel due to the aerosol generating nature of the procedure. We describe a protocol with unique and novel modifications to the Ciaglia dilatational percutaneous tracheostomy, effectively implemented during the Covid-19 pandemic at our institution. METHODS: We describe the baseline characteristics of our initial 11 patients who underwent the procedure. Outlined are the healthcare personnel involved and the steps which are organized into 4 phases: planning, pre-procedure, intra-procedure and post-procedure. We have tracked procedural duration, provider safety as well as the development of new complications. RESULTS: We describe use of this protocol for 11 bedside percutaneous tracheostomies performed on patients with COVID-19. The average total procedural duration as well as incision to tracheostomy tube placement times was 32.6 minutes and 5.8 minutes respectively. All 3 providers performing the tracheostomies remained asymptomatic with negative COVID-19 RT-PCR testing at 3 weeks. CONCLUSIONS: We report an efficacious and adaptable protocol for elective bedside percutaneous tracheostomies for patients with persistent ventilatory requirements due to COVID-19 with an intent to provide standardized and safe care for the patient and the involved healthcare personnel.


Subject(s)
COVID-19 , Critical Pathways , Occupational Exposure/prevention & control , Personal Protective Equipment/standards , Respiratory Insufficiency , Tracheostomy , COVID-19/complications , COVID-19/physiopathology , COVID-19/prevention & control , Critical Pathways/organization & administration , Critical Pathways/trends , Female , Health Personnel , Humans , Infection Control/methods , Male , Middle Aged , Patient Care Team/organization & administration , Proof of Concept Study , Respiratory Insufficiency/etiology , Respiratory Insufficiency/therapy , SARS-CoV-2/isolation & purification , Safety Management , Tracheostomy/methods , Tracheostomy/trends , United States
20.
J Plast Reconstr Aesthet Surg ; 74(3): 644-710, 2021 03.
Article in English | MEDLINE | ID: mdl-33221182

ABSTRACT

During the recovery restitution phase of the coronavirus pandemic, breast reconstruction teams have faced particular challenges to restarting this essential service. This is due to the length and complexity of the surgery, along with the demands on healthcare staff. The Royal College of Surgeons have classified immediate breast reconstruction as priority 2 and the National Institute for Health and Care Excellence have provided a pre-operative pathway for resumption of elective procedures. We therefore describe our experience in restarting our service for providing a breast reconstruction service from the 29th June 2020.


Subject(s)
Breast Neoplasms , COVID-19 , Critical Pathways , Elective Surgical Procedures , Mammaplasty , Breast Neoplasms/epidemiology , Breast Neoplasms/surgery , COVID-19/epidemiology , COVID-19/prevention & control , Critical Pathways/organization & administration , Critical Pathways/trends , Elective Surgical Procedures/methods , Elective Surgical Procedures/statistics & numerical data , Female , Humans , Infection Control/methods , Infection Control/organization & administration , Mammaplasty/methods , Mammaplasty/statistics & numerical data , Organizational Innovation , Outcome and Process Assessment, Health Care , SARS-CoV-2 , State Medicine/organization & administration , State Medicine/trends , United Kingdom/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...